Biomarker-driven prescribing in oncology is playing an increasingly important role in various diseases, from indications in which its use is well entranced such as non-small-cell lung cancer (NSCLC), to indications that more recently incorporated the use of predicative biomarkers, such as malignant melanoma and ovarian cancer. However, these therapies are premium-priced and often face reimbursement restrictions in the EU5. Several recently EC-approved and emerging biomarker-targeted therapies are aiming to be incorporated into the treatment algorithm. Will these agents be met with increased reimbursement restrictions as the cost-consciousness of EU5 payers’ heightens in the current economic climate? This Access & Reimbursement module examines the factors that influence the success of current and emerging biomarker-driven therapies in NSCLC, ovarian cancer, and malignant melanoma. Based on insights from surveyed oncologists and interviewed payers across the EU5, this research explores how both parties shape the access environment for each disease, and how reimbursement decisions impact the prescribing and uptake of specific therapies at the brand level.
Table of contents
- Biomarkers In Oncology - Access & Reimbursement - Detailed Expanded Analysis Biomarkers In Oncology: Malignant Melanoma, Non-Small-Cell Lung Cancer, Ovarian Cancer (EU5)
Author(s): Izabela Ammermann, PhD
Izabela Ammermann, Ph.D., M.Sc., is a business insights analyst in the oncology division at Decision Resources Group. She is a specialist in multiple myeloma and pancreatic cancer and has expertise in chronic lymphocytic leukemia. Dr. Ammermann holds a Ph.D. in molecular biology from the Technical University of Munich and a M.Sc. in biotechnology from the Polish Academy of Sciences. Prior to joining Decision Resources Group, Dr. Ammermann worked as a postdoctoral research associate (Marie Curie research fellow) at Imperial College London. Dr. Ammermann has published several peer-reviewed papers.